| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney Transplantation | 195 | 2024 | 4300 | 5.520 |
Why?
|
| Transplantation Chimera | 35 | 2021 | 594 | 3.850 |
Why?
|
| Transplantation Tolerance | 32 | 2024 | 633 | 3.810 |
Why?
|
| Graft Survival | 64 | 2021 | 3900 | 2.450 |
Why?
|
| Bone Marrow Transplantation | 43 | 2019 | 2709 | 2.440 |
Why?
|
| Graft Rejection | 99 | 2024 | 4505 | 2.360 |
Why?
|
| Liver Transplantation | 51 | 2017 | 2400 | 2.160 |
Why?
|
| Immunosuppressive Agents | 64 | 2021 | 4209 | 1.970 |
Why?
|
| Macaca fascicularis | 65 | 2019 | 913 | 1.800 |
Why?
|
| Immune Tolerance | 33 | 2019 | 2324 | 1.410 |
Why?
|
| Histocompatibility Testing | 19 | 2019 | 716 | 1.280 |
Why?
|
| Transplantation, Homologous | 79 | 2022 | 4834 | 1.260 |
Why?
|
| Antilymphocyte Serum | 29 | 2016 | 491 | 1.190 |
Why?
|
| Isoantibodies | 17 | 2021 | 682 | 1.140 |
Why?
|
| Antibodies, Monoclonal | 55 | 2015 | 9261 | 1.080 |
Why?
|
| Organ Transplantation | 12 | 2022 | 1177 | 1.040 |
Why?
|
| Transplantation Conditioning | 24 | 2019 | 1600 | 0.950 |
Why?
|
| Chimerism | 11 | 2023 | 156 | 0.950 |
Why?
|
| HLA Antigens | 21 | 2021 | 1337 | 0.880 |
Why?
|
| Kidney Failure, Chronic | 15 | 2019 | 2491 | 0.850 |
Why?
|
| Transplantation, Heterologous | 18 | 2017 | 2394 | 0.750 |
Why?
|
| Transplantation Immunology | 11 | 2015 | 538 | 0.710 |
Why?
|
| Living Donors | 7 | 2012 | 651 | 0.610 |
Why?
|
| Tissue Donors | 23 | 2015 | 2389 | 0.570 |
Why?
|
| Nobel Prize | 2 | 2006 | 46 | 0.530 |
Why?
|
| CD40 Ligand | 6 | 2016 | 524 | 0.530 |
Why?
|
| Transplantation | 3 | 2008 | 221 | 0.520 |
Why?
|
| T-Lymphocytes | 39 | 2015 | 10267 | 0.490 |
Why?
|
| Hepatitis C | 14 | 2008 | 1593 | 0.490 |
Why?
|
| Pancreas Transplantation | 7 | 1998 | 198 | 0.470 |
Why?
|
| Primates | 8 | 2023 | 521 | 0.470 |
Why?
|
| Cyclosporine | 16 | 2015 | 779 | 0.460 |
Why?
|
| Histocompatibility | 4 | 2021 | 322 | 0.460 |
Why?
|
| Kidney Diseases | 14 | 2014 | 2103 | 0.430 |
Why?
|
| Receptors, Tumor Necrosis Factor | 4 | 1997 | 588 | 0.420 |
Why?
|
| Muromonab-CD3 | 8 | 2000 | 104 | 0.420 |
Why?
|
| Sentinel Lymph Node Biopsy | 6 | 2015 | 740 | 0.410 |
Why?
|
| Bloodletting | 1 | 2011 | 22 | 0.380 |
Why?
|
| Cyclosporins | 11 | 1991 | 216 | 0.380 |
Why?
|
| Complement C4b | 9 | 2009 | 125 | 0.360 |
Why?
|
| Multiple Myeloma | 6 | 2019 | 5192 | 0.350 |
Why?
|
| Phlebotomy | 1 | 2011 | 138 | 0.350 |
Why?
|
| Blood Cell Count | 1 | 2011 | 402 | 0.350 |
Why?
|
| Receptors, Interleukin-2 | 8 | 1995 | 564 | 0.330 |
Why?
|
| Blood Chemical Analysis | 1 | 2011 | 436 | 0.320 |
Why?
|
| Bile Duct Neoplasms | 2 | 2005 | 616 | 0.320 |
Why?
|
| Hospital Charges | 1 | 2011 | 351 | 0.320 |
Why?
|
| Animals | 110 | 2024 | 169337 | 0.320 |
Why?
|
| Immunologic Memory | 8 | 2015 | 1374 | 0.310 |
Why?
|
| Kidney | 31 | 2019 | 7064 | 0.300 |
Why?
|
| Whole-Body Irradiation | 11 | 2014 | 435 | 0.300 |
Why?
|
| Altruism | 1 | 2009 | 212 | 0.290 |
Why?
|
| Melanoma | 14 | 2015 | 5705 | 0.280 |
Why?
|
| Liver Failure, Acute | 2 | 2012 | 182 | 0.280 |
Why?
|
| Awareness | 1 | 2011 | 653 | 0.270 |
Why?
|
| Postoperative Complications | 31 | 2019 | 15881 | 0.270 |
Why?
|
| Blood Coagulation Factors | 4 | 2017 | 366 | 0.260 |
Why?
|
| Interleukin-2 | 5 | 2015 | 1894 | 0.260 |
Why?
|
| Allergy and Immunology | 1 | 2008 | 175 | 0.260 |
Why?
|
| Papio | 12 | 2017 | 672 | 0.260 |
Why?
|
| Cell Adhesion Molecules | 7 | 1995 | 1614 | 0.260 |
Why?
|
| Cytomegalovirus Infections | 19 | 2017 | 839 | 0.260 |
Why?
|
| Models, Animal | 8 | 2017 | 2124 | 0.250 |
Why?
|
| Cystic Duct | 1 | 2005 | 18 | 0.250 |
Why?
|
| Hospital Costs | 1 | 2011 | 959 | 0.240 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 9 | 1989 | 896 | 0.240 |
Why?
|
| Antibodies, Heterophile | 7 | 1999 | 128 | 0.240 |
Why?
|
| Humans | 226 | 2022 | 768393 | 0.240 |
Why?
|
| Tissue and Organ Harvesting | 2 | 2008 | 374 | 0.240 |
Why?
|
| Skin Neoplasms | 13 | 2015 | 5857 | 0.230 |
Why?
|
| Tissue and Organ Procurement | 6 | 2015 | 986 | 0.230 |
Why?
|
| Liver Neoplasms | 7 | 2010 | 4365 | 0.230 |
Why?
|
| Killer Cells, Natural | 5 | 2018 | 2206 | 0.230 |
Why?
|
| Cholangitis, Sclerosing | 1 | 2006 | 179 | 0.220 |
Why?
|
| Lymph Nodes | 9 | 2015 | 3471 | 0.220 |
Why?
|
| Ethics, Medical | 4 | 2009 | 785 | 0.220 |
Why?
|
| Hyperoxaluria, Primary | 2 | 2013 | 25 | 0.220 |
Why?
|
| Immunotoxins | 2 | 2012 | 175 | 0.210 |
Why?
|
| Lymph Node Excision | 3 | 2015 | 1274 | 0.210 |
Why?
|
| Antibodies | 12 | 2022 | 2425 | 0.200 |
Why?
|
| Carcinoma, Hepatocellular | 5 | 2010 | 2336 | 0.200 |
Why?
|
| Creatinine | 15 | 2012 | 1915 | 0.200 |
Why?
|
| Cholestasis | 2 | 2005 | 385 | 0.200 |
Why?
|
| Islets of Langerhans Transplantation | 3 | 2016 | 748 | 0.200 |
Why?
|
| Lymphopoiesis | 1 | 2002 | 133 | 0.200 |
Why?
|
| History, 20th Century | 5 | 2015 | 2771 | 0.190 |
Why?
|
| Antiviral Agents | 13 | 2017 | 3064 | 0.190 |
Why?
|
| Male | 125 | 2019 | 364902 | 0.190 |
Why?
|
| T-Lymphocytes, Regulatory | 9 | 2019 | 3112 | 0.190 |
Why?
|
| Thrombophilia | 1 | 2004 | 306 | 0.180 |
Why?
|
| Lung Transplantation | 4 | 2015 | 1309 | 0.180 |
Why?
|
| Portal Vein | 2 | 2013 | 432 | 0.180 |
Why?
|
| Glomerulonephritis | 3 | 2002 | 333 | 0.180 |
Why?
|
| Postoperative Care | 4 | 2009 | 1480 | 0.180 |
Why?
|
| Nephrectomy | 3 | 2012 | 949 | 0.180 |
Why?
|
| Middle Aged | 87 | 2019 | 223491 | 0.180 |
Why?
|
| Immunologic Techniques | 2 | 1999 | 213 | 0.180 |
Why?
|
| Intraoperative Care | 2 | 2003 | 771 | 0.170 |
Why?
|
| Tacrolimus | 5 | 2004 | 750 | 0.170 |
Why?
|
| Survival Rate | 15 | 2017 | 12870 | 0.170 |
Why?
|
| Mycophenolic Acid | 5 | 2004 | 350 | 0.170 |
Why?
|
| Hepatectomy | 1 | 2003 | 588 | 0.170 |
Why?
|
| Antibodies, Anti-Idiotypic | 5 | 1990 | 355 | 0.170 |
Why?
|
| Major Histocompatibility Complex | 7 | 2019 | 877 | 0.170 |
Why?
|
| Immunoconjugates | 2 | 2014 | 969 | 0.170 |
Why?
|
| Waiting Lists | 4 | 2015 | 780 | 0.160 |
Why?
|
| Lymphocyte Depletion | 7 | 2010 | 605 | 0.160 |
Why?
|
| Hepatitis B, Chronic | 1 | 2003 | 413 | 0.160 |
Why?
|
| Adult | 94 | 2019 | 223640 | 0.160 |
Why?
|
| Time Factors | 39 | 2018 | 40272 | 0.160 |
Why?
|
| Interferon-alpha | 5 | 2004 | 910 | 0.160 |
Why?
|
| Viremia | 4 | 1998 | 725 | 0.160 |
Why?
|
| Splenectomy | 7 | 2010 | 392 | 0.150 |
Why?
|
| Cholestasis, Intrahepatic | 1 | 1998 | 75 | 0.150 |
Why?
|
| Health Expenditures | 1 | 2011 | 2395 | 0.150 |
Why?
|
| Venous Thrombosis | 2 | 2006 | 1317 | 0.150 |
Why?
|
| Chimera | 6 | 1999 | 454 | 0.150 |
Why?
|
| Immunoglobulin G | 12 | 2000 | 4570 | 0.150 |
Why?
|
| Cardiolipins | 1 | 1997 | 83 | 0.150 |
Why?
|
| Hematopoiesis | 2 | 2019 | 2058 | 0.150 |
Why?
|
| Antibody Formation | 10 | 2002 | 1393 | 0.150 |
Why?
|
| Lymphocyte Transfusion | 1 | 1998 | 232 | 0.140 |
Why?
|
| Treatment Outcome | 23 | 2021 | 65379 | 0.140 |
Why?
|
| Thromboembolism | 2 | 2004 | 1004 | 0.140 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 3 | 2023 | 5713 | 0.140 |
Why?
|
| Recombinant Fusion Proteins | 7 | 2013 | 3731 | 0.140 |
Why?
|
| Flow Cytometry | 13 | 2015 | 5900 | 0.140 |
Why?
|
| Graft vs Host Reaction | 1 | 1997 | 99 | 0.140 |
Why?
|
| Enzyme Inhibitors | 2 | 2010 | 3722 | 0.140 |
Why?
|
| Resource Allocation | 3 | 2015 | 354 | 0.140 |
Why?
|
| Immunoglobulin M | 5 | 2000 | 1528 | 0.130 |
Why?
|
| Portacaval Shunt, Surgical | 1 | 1996 | 46 | 0.130 |
Why?
|
| Hepatic Artery | 1 | 1997 | 232 | 0.130 |
Why?
|
| History, 21st Century | 3 | 2015 | 1575 | 0.130 |
Why?
|
| Female | 93 | 2019 | 397089 | 0.130 |
Why?
|
| Hepatitis, Chronic | 1 | 1996 | 53 | 0.130 |
Why?
|
| Ganciclovir | 4 | 2000 | 256 | 0.130 |
Why?
|
| Swine | 13 | 2017 | 5994 | 0.130 |
Why?
|
| Complement Activation | 5 | 2001 | 447 | 0.130 |
Why?
|
| Receptors, Fc | 2 | 1989 | 538 | 0.130 |
Why?
|
| Complement C4 | 6 | 2002 | 216 | 0.130 |
Why?
|
| Vascular Diseases | 2 | 2022 | 1161 | 0.130 |
Why?
|
| Histocompatibility Antigens | 1 | 2017 | 478 | 0.130 |
Why?
|
| Endothelium | 2 | 2018 | 768 | 0.120 |
Why?
|
| Lymphocyte Culture Test, Mixed | 4 | 2006 | 510 | 0.120 |
Why?
|
| B-Cell Activating Factor | 1 | 2015 | 116 | 0.120 |
Why?
|
| Peptide Fragments | 9 | 2009 | 5151 | 0.120 |
Why?
|
| Intercellular Adhesion Molecule-1 | 7 | 1995 | 1133 | 0.120 |
Why?
|
| Follow-Up Studies | 18 | 2019 | 39407 | 0.120 |
Why?
|
| Lymphedema | 2 | 2000 | 527 | 0.120 |
Why?
|
| Patient Selection | 6 | 2009 | 4266 | 0.120 |
Why?
|
| Adenoma | 2 | 2005 | 2163 | 0.120 |
Why?
|
| Gene Expression Profiling | 4 | 2018 | 9510 | 0.120 |
Why?
|
| Haplorhini | 5 | 2009 | 524 | 0.120 |
Why?
|
| General Surgery | 1 | 2006 | 1713 | 0.120 |
Why?
|
| Death | 2 | 2010 | 683 | 0.120 |
Why?
|
| Leukocyte Count | 9 | 2011 | 1605 | 0.110 |
Why?
|
| Acute Disease | 12 | 2003 | 7242 | 0.110 |
Why?
|
| Guanidines | 4 | 1999 | 194 | 0.110 |
Why?
|
| CD8-Positive T-Lymphocytes | 5 | 2024 | 4646 | 0.110 |
Why?
|
| Embolization, Therapeutic | 2 | 2013 | 1410 | 0.110 |
Why?
|
| Nephrotic Syndrome | 1 | 1997 | 382 | 0.110 |
Why?
|
| Cadaver | 7 | 2009 | 1366 | 0.110 |
Why?
|
| Tissue Survival | 1 | 2013 | 120 | 0.110 |
Why?
|
| Health Care Rationing | 1 | 1996 | 435 | 0.110 |
Why?
|
| Registries | 3 | 2015 | 8379 | 0.110 |
Why?
|
| T-Lymphocytes, Cytotoxic | 5 | 2024 | 1795 | 0.110 |
Why?
|
| Antigens, Differentiation | 3 | 1999 | 921 | 0.110 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 2 | 2010 | 631 | 0.110 |
Why?
|
| Hand-Assisted Laparoscopy | 1 | 2012 | 15 | 0.100 |
Why?
|
| Ribavirin | 3 | 2003 | 395 | 0.100 |
Why?
|
| Drug Therapy, Combination | 9 | 2018 | 6318 | 0.100 |
Why?
|
| Nevus | 1 | 2014 | 205 | 0.100 |
Why?
|
| Thymus Gland | 5 | 2007 | 1266 | 0.100 |
Why?
|
| ABO Blood-Group System | 4 | 2006 | 381 | 0.100 |
Why?
|
| Ureterostomy | 1 | 2012 | 18 | 0.100 |
Why?
|
| Cystostomy | 1 | 2012 | 25 | 0.100 |
Why?
|
| Chronic Disease | 12 | 2017 | 9379 | 0.100 |
Why?
|
| Hypertension, Malignant | 1 | 2012 | 17 | 0.100 |
Why?
|
| Membrane Glycoproteins | 2 | 2000 | 3712 | 0.100 |
Why?
|
| Hepacivirus | 4 | 2008 | 1342 | 0.100 |
Why?
|
| Myeloablative Agonists | 1 | 2013 | 210 | 0.100 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 8 | 2009 | 3813 | 0.100 |
Why?
|
| Prognosis | 13 | 2015 | 30022 | 0.100 |
Why?
|
| Azathioprine | 5 | 1994 | 354 | 0.100 |
Why?
|
| Capillary Leak Syndrome | 1 | 2011 | 34 | 0.090 |
Why?
|
| Diphtheria Toxin | 1 | 2012 | 253 | 0.090 |
Why?
|
| Defensive Medicine | 1 | 2011 | 47 | 0.090 |
Why?
|
| Retrospective Studies | 33 | 2019 | 81801 | 0.090 |
Why?
|
| Ureter | 2 | 2012 | 370 | 0.090 |
Why?
|
| Steroids | 4 | 2001 | 937 | 0.090 |
Why?
|
| Diabetes Mellitus, Type 1 | 7 | 1998 | 3440 | 0.090 |
Why?
|
| Galactosyltransferases | 1 | 2012 | 284 | 0.090 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2014 | 594 | 0.090 |
Why?
|
| Thrombocytopenia | 2 | 2016 | 1180 | 0.090 |
Why?
|
| Lymphatic Metastasis | 6 | 2015 | 2925 | 0.090 |
Why?
|
| Antibody Specificity | 6 | 2005 | 1065 | 0.090 |
Why?
|
| Mesentery | 1 | 2011 | 202 | 0.090 |
Why?
|
| Horses | 3 | 2015 | 296 | 0.090 |
Why?
|
| Opportunistic Infections | 2 | 2008 | 375 | 0.090 |
Why?
|
| Diabetes Mellitus | 4 | 2016 | 5891 | 0.080 |
Why?
|
| B-Lymphocytes | 6 | 2015 | 4785 | 0.080 |
Why?
|
| Liver Cirrhosis | 2 | 2008 | 1959 | 0.080 |
Why?
|
| Biopsy | 17 | 2008 | 6808 | 0.080 |
Why?
|
| Stem Cell Factor | 1 | 2010 | 194 | 0.080 |
Why?
|
| Syndrome | 4 | 2005 | 3275 | 0.080 |
Why?
|
| Sirolimus | 1 | 2016 | 1542 | 0.080 |
Why?
|
| Carcinoid Tumor | 1 | 2011 | 224 | 0.080 |
Why?
|
| Heart Transplantation | 5 | 2002 | 3300 | 0.080 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2010 | 225 | 0.080 |
Why?
|
| Pathology, Clinical | 1 | 2012 | 376 | 0.080 |
Why?
|
| Cytotoxicity, Immunologic | 9 | 2000 | 1355 | 0.080 |
Why?
|
| Graft vs Host Disease | 2 | 2017 | 3044 | 0.080 |
Why?
|
| Acyclovir | 3 | 2000 | 267 | 0.080 |
Why?
|
| Hepatitis B | 1 | 1994 | 708 | 0.080 |
Why?
|
| Cost Control | 1 | 2011 | 627 | 0.080 |
Why?
|
| Disaccharides | 2 | 2000 | 170 | 0.080 |
Why?
|
| Vena Cava, Inferior | 2 | 2006 | 463 | 0.080 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2010 | 414 | 0.080 |
Why?
|
| Lymphocele | 1 | 2008 | 19 | 0.080 |
Why?
|
| Hepatitis, Viral, Human | 2 | 1988 | 141 | 0.080 |
Why?
|
| Prednisone | 5 | 2000 | 1567 | 0.070 |
Why?
|
| RNA | 1 | 2018 | 2726 | 0.070 |
Why?
|
| Physicians | 1 | 2006 | 4614 | 0.070 |
Why?
|
| Dermatomycoses | 1 | 2008 | 45 | 0.070 |
Why?
|
| Kidney Function Tests | 4 | 2015 | 681 | 0.070 |
Why?
|
| Aspergillus | 1 | 2008 | 95 | 0.070 |
Why?
|
| Tumor Virus Infections | 2 | 2001 | 438 | 0.070 |
Why?
|
| Unnecessary Procedures | 1 | 2011 | 419 | 0.070 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2012 | 749 | 0.070 |
Why?
|
| Hematologic Neoplasms | 1 | 2019 | 1905 | 0.070 |
Why?
|
| Brain Death | 1 | 2010 | 360 | 0.070 |
Why?
|
| Thrombosis | 2 | 1999 | 2955 | 0.070 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 1997 | 4357 | 0.070 |
Why?
|
| alpha 1-Antitrypsin Deficiency | 1 | 2008 | 113 | 0.070 |
Why?
|
| Lymphocytes | 6 | 1998 | 2611 | 0.070 |
Why?
|
| Reoperation | 5 | 2012 | 4341 | 0.070 |
Why?
|
| RNA, Messenger | 3 | 2019 | 12805 | 0.070 |
Why?
|
| Oxygen Consumption | 1 | 2013 | 1882 | 0.070 |
Why?
|
| Receptors, Antigen, T-Cell | 3 | 1994 | 2568 | 0.070 |
Why?
|
| Glomerular Filtration Rate | 4 | 2015 | 2226 | 0.070 |
Why?
|
| Lymphoma, B-Cell | 1 | 1993 | 945 | 0.070 |
Why?
|
| CD4-Positive T-Lymphocytes | 4 | 2012 | 4411 | 0.070 |
Why?
|
| Mice | 15 | 2024 | 82017 | 0.070 |
Why?
|
| Actuarial Analysis | 2 | 1996 | 372 | 0.060 |
Why?
|
| Forecasting | 2 | 2011 | 2948 | 0.060 |
Why?
|
| Boston | 6 | 2012 | 9371 | 0.060 |
Why?
|
| Lung Diseases | 2 | 2015 | 1925 | 0.060 |
Why?
|
| Aspergillosis | 1 | 2008 | 242 | 0.060 |
Why?
|
| Aged | 30 | 2019 | 171562 | 0.060 |
Why?
|
| Nephritis, Hereditary | 1 | 2006 | 78 | 0.060 |
Why?
|
| Cytomegalovirus | 7 | 2000 | 754 | 0.060 |
Why?
|
| Kidney Glomerulus | 5 | 1998 | 569 | 0.060 |
Why?
|
| France | 1 | 2006 | 497 | 0.060 |
Why?
|
| Recombinant Proteins | 5 | 2003 | 6510 | 0.060 |
Why?
|
| Clinical Trials as Topic | 11 | 2017 | 8051 | 0.060 |
Why?
|
| Plasmacytoma | 1 | 2006 | 170 | 0.060 |
Why?
|
| Hemorrhage | 2 | 2016 | 3461 | 0.060 |
Why?
|
| RNA, Viral | 2 | 2008 | 2866 | 0.060 |
Why?
|
| Hemophilia A | 1 | 1988 | 359 | 0.060 |
Why?
|
| Haplotypes | 1 | 2011 | 2724 | 0.060 |
Why?
|
| Hepatoblastoma | 1 | 2005 | 90 | 0.060 |
Why?
|
| Hemangioendothelioma, Epithelioid | 1 | 2005 | 54 | 0.060 |
Why?
|
| Ketorolac Tromethamine | 1 | 2004 | 21 | 0.060 |
Why?
|
| Immunity, Cellular | 6 | 2001 | 1561 | 0.060 |
Why?
|
| Swine, Miniature | 3 | 2016 | 965 | 0.060 |
Why?
|
| Peritoneal Neoplasms | 1 | 2011 | 715 | 0.060 |
Why?
|
| Neoplasm Staging | 7 | 2012 | 11254 | 0.060 |
Why?
|
| Alprostadil | 1 | 2004 | 86 | 0.060 |
Why?
|
| United States | 8 | 2015 | 73150 | 0.060 |
Why?
|
| Blood Vessels | 2 | 1999 | 1110 | 0.060 |
Why?
|
| Lymphatic Vessels | 1 | 2008 | 356 | 0.060 |
Why?
|
| Incidence | 7 | 2015 | 21544 | 0.060 |
Why?
|
| Reproductive Behavior | 1 | 2003 | 27 | 0.050 |
Why?
|
| History, 19th Century | 1 | 2006 | 715 | 0.050 |
Why?
|
| Cryoglobulinemia | 2 | 2002 | 84 | 0.050 |
Why?
|
| Intestines | 2 | 2011 | 1912 | 0.050 |
Why?
|
| Islets of Langerhans | 3 | 2010 | 1350 | 0.050 |
Why?
|
| Immunoglobulin Idiotypes | 3 | 1989 | 201 | 0.050 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 1993 | 1428 | 0.050 |
Why?
|
| Neutropenia | 1 | 2008 | 893 | 0.050 |
Why?
|
| Australia | 1 | 2006 | 1265 | 0.050 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2006 | 1855 | 0.050 |
Why?
|
| Genes, bcl-2 | 1 | 2023 | 119 | 0.050 |
Why?
|
| Monitoring, Physiologic | 3 | 2006 | 1795 | 0.050 |
Why?
|
| Drug Costs | 1 | 2011 | 1196 | 0.050 |
Why?
|
| Porphyria, Hepatoerythropoietic | 1 | 2002 | 8 | 0.050 |
Why?
|
| Cyclophosphamide | 1 | 2008 | 2226 | 0.050 |
Why?
|
| Length of Stay | 4 | 2003 | 6519 | 0.050 |
Why?
|
| Hemin | 1 | 2002 | 51 | 0.050 |
Why?
|
| Complement C3b | 2 | 1999 | 98 | 0.050 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2008 | 617 | 0.050 |
Why?
|
| Insulin Resistance | 2 | 2008 | 3981 | 0.050 |
Why?
|
| Skin Transplantation | 3 | 2009 | 1097 | 0.050 |
Why?
|
| Combined Modality Therapy | 5 | 2013 | 8562 | 0.050 |
Why?
|
| Dose-Response Relationship, Immunologic | 4 | 2006 | 359 | 0.050 |
Why?
|
| Menstruation | 1 | 2003 | 310 | 0.050 |
Why?
|
| Delayed Graft Function | 2 | 2012 | 53 | 0.050 |
Why?
|
| Receptors, Immunologic | 2 | 1988 | 1416 | 0.050 |
Why?
|
| Diabetic Nephropathies | 2 | 1988 | 975 | 0.050 |
Why?
|
| Animals, Genetically Modified | 2 | 2017 | 1563 | 0.050 |
Why?
|
| Contraception Behavior | 1 | 2003 | 187 | 0.050 |
Why?
|
| Prospective Studies | 14 | 2008 | 54920 | 0.050 |
Why?
|
| Fallopian Tube Diseases | 1 | 2001 | 60 | 0.050 |
Why?
|
| Interferon-gamma | 2 | 2024 | 3164 | 0.050 |
Why?
|
| Food Hypersensitivity | 1 | 2009 | 733 | 0.050 |
Why?
|
| Survival Analysis | 4 | 2004 | 10117 | 0.050 |
Why?
|
| BK Virus | 1 | 2001 | 120 | 0.050 |
Why?
|
| Complement System Proteins | 2 | 2001 | 738 | 0.050 |
Why?
|
| Pseudomonas Infections | 2 | 2001 | 623 | 0.040 |
Why?
|
| Patient Compliance | 3 | 2009 | 2693 | 0.040 |
Why?
|
| Acute Kidney Injury | 2 | 2011 | 1943 | 0.040 |
Why?
|
| Transplantation, Autologous | 3 | 2015 | 2127 | 0.040 |
Why?
|
| Antigens, CD | 3 | 1999 | 4031 | 0.040 |
Why?
|
| Ovarian Diseases | 1 | 2001 | 137 | 0.040 |
Why?
|
| Decision Support Techniques | 1 | 2010 | 2006 | 0.040 |
Why?
|
| Leukopenia | 2 | 2000 | 212 | 0.040 |
Why?
|
| Adaptation, Physiological | 1 | 2007 | 1315 | 0.040 |
Why?
|
| Growth Substances | 2 | 1999 | 761 | 0.040 |
Why?
|
| Isoantigens | 3 | 2011 | 563 | 0.040 |
Why?
|
| Polyomavirus Infections | 1 | 2001 | 192 | 0.040 |
Why?
|
| Cholangiocarcinoma | 1 | 2005 | 562 | 0.040 |
Why?
|
| Esophageal Diseases | 1 | 2000 | 168 | 0.040 |
Why?
|
| Adolescent | 16 | 2015 | 89184 | 0.040 |
Why?
|
| Epitopes | 4 | 1999 | 2525 | 0.040 |
Why?
|
| Dactinomycin | 2 | 1998 | 305 | 0.040 |
Why?
|
| Renal Circulation | 1 | 1999 | 291 | 0.040 |
Why?
|
| Premenopause | 1 | 2003 | 1039 | 0.040 |
Why?
|
| Cell Separation | 3 | 2001 | 1726 | 0.040 |
Why?
|
| Antibodies, Anticardiolipin | 1 | 1999 | 62 | 0.040 |
Why?
|
| Bone Marrow Cells | 2 | 2013 | 2414 | 0.040 |
Why?
|
| Ulcer | 1 | 2000 | 203 | 0.040 |
Why?
|
| Complement Membrane Attack Complex | 1 | 1999 | 105 | 0.040 |
Why?
|
| GATA3 Transcription Factor | 1 | 2019 | 163 | 0.040 |
Why?
|
| Cells, Cultured | 6 | 2017 | 19022 | 0.040 |
Why?
|
| Hepatitis C Antibodies | 1 | 1998 | 151 | 0.040 |
Why?
|
| Recurrence | 6 | 2003 | 8506 | 0.040 |
Why?
|
| Drug Combinations | 2 | 2004 | 2079 | 0.040 |
Why?
|
| Forkhead Transcription Factors | 2 | 2019 | 1623 | 0.040 |
Why?
|
| Renal Artery | 2 | 1999 | 353 | 0.040 |
Why?
|
| End Stage Liver Disease | 2 | 2015 | 370 | 0.040 |
Why?
|
| Polyomavirus | 1 | 1999 | 235 | 0.040 |
Why?
|
| Rabbits | 2 | 2016 | 4781 | 0.040 |
Why?
|
| Disseminated Intravascular Coagulation | 1 | 1998 | 187 | 0.040 |
Why?
|
| Massage | 1 | 1998 | 86 | 0.040 |
Why?
|
| Plasma Exchange | 1 | 1998 | 160 | 0.040 |
Why?
|
| Abscess | 1 | 2001 | 606 | 0.040 |
Why?
|
| Gene Expression Regulation | 1 | 2015 | 11918 | 0.040 |
Why?
|
| Methylprednisolone | 3 | 2001 | 387 | 0.040 |
Why?
|
| Chromatography, Affinity | 1 | 1998 | 525 | 0.030 |
Why?
|
| Child | 11 | 2015 | 80891 | 0.030 |
Why?
|
| Pancytopenia | 1 | 1997 | 102 | 0.030 |
Why?
|
| Bioethics | 1 | 1998 | 118 | 0.030 |
Why?
|
| Lymphocyte Activation | 5 | 1999 | 5496 | 0.030 |
Why?
|
| Heparin | 1 | 2004 | 1636 | 0.030 |
Why?
|
| False Negative Reactions | 2 | 2012 | 575 | 0.030 |
Why?
|
| Risk Assessment | 5 | 2015 | 24318 | 0.030 |
Why?
|
| Neoplasm Metastasis | 2 | 2005 | 4921 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2010 | 9433 | 0.030 |
Why?
|
| Disease Models, Animal | 5 | 2017 | 18362 | 0.030 |
Why?
|
| Hospitals, General | 1 | 2001 | 807 | 0.030 |
Why?
|
| Immunization | 3 | 2001 | 1219 | 0.030 |
Why?
|
| Constriction | 1 | 1996 | 168 | 0.030 |
Why?
|
| Bandages | 1 | 1998 | 273 | 0.030 |
Why?
|
| Hodgkin Disease | 1 | 1984 | 1386 | 0.030 |
Why?
|
| Histocompatibility Antigens Class II | 2 | 1999 | 1438 | 0.030 |
Why?
|
| Urinary Tract Infections | 4 | 1992 | 806 | 0.030 |
Why?
|
| Hepatitis C, Chronic | 1 | 2004 | 1031 | 0.030 |
Why?
|
| Cytotoxicity Tests, Immunologic | 2 | 1994 | 317 | 0.030 |
Why?
|
| Technetium Tc 99m Pentetate | 1 | 1995 | 67 | 0.030 |
Why?
|
| Bone Marrow | 2 | 2019 | 2929 | 0.030 |
Why?
|
| Antigens, Surface | 5 | 1987 | 1616 | 0.030 |
Why?
|
| Enalapril | 1 | 1997 | 316 | 0.030 |
Why?
|
| Kidney Tubular Necrosis, Acute | 2 | 2011 | 65 | 0.030 |
Why?
|
| Social Values | 1 | 1996 | 224 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2012 | 6541 | 0.030 |
Why?
|
| Thrombophlebitis | 1 | 1996 | 289 | 0.030 |
Why?
|
| Dimerization | 1 | 1997 | 886 | 0.030 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 1998 | 892 | 0.030 |
Why?
|
| Fatal Outcome | 3 | 2009 | 1837 | 0.030 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2001 | 1122 | 0.030 |
Why?
|
| Young Adult | 4 | 2015 | 60049 | 0.030 |
Why?
|
| Hepatitis B Surface Antigens | 2 | 1994 | 294 | 0.030 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 1 | 1998 | 336 | 0.030 |
Why?
|
| Liver Function Tests | 4 | 2002 | 526 | 0.030 |
Why?
|
| Transforming Growth Factor beta | 2 | 2019 | 2003 | 0.030 |
Why?
|
| Hepatitis Delta Virus | 1 | 1994 | 24 | 0.030 |
Why?
|
| Renal Dialysis | 3 | 2002 | 1802 | 0.030 |
Why?
|
| Proteinuria | 1 | 1997 | 613 | 0.030 |
Why?
|
| Health Care Costs | 1 | 2007 | 3267 | 0.030 |
Why?
|
| Interleukin-10 | 1 | 2019 | 1184 | 0.030 |
Why?
|
| Demography | 1 | 1999 | 1642 | 0.030 |
Why?
|
| Quality of Life | 2 | 1996 | 13503 | 0.030 |
Why?
|
| Gene Transfer Techniques | 1 | 1999 | 1209 | 0.030 |
Why?
|
| Rodentia | 1 | 1995 | 262 | 0.030 |
Why?
|
| Binding Sites, Antibody | 1 | 1994 | 340 | 0.030 |
Why?
|
| Injections, Subcutaneous | 1 | 2015 | 687 | 0.030 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2015 | 224 | 0.030 |
Why?
|
| Microscopy, Electron | 4 | 1999 | 2559 | 0.030 |
Why?
|
| Biphenyl Compounds | 1 | 1998 | 1026 | 0.030 |
Why?
|
| Anemia, Sickle Cell | 1 | 2002 | 1065 | 0.030 |
Why?
|
| Oxalates | 1 | 2013 | 99 | 0.030 |
Why?
|
| Solubility | 1 | 1995 | 1085 | 0.030 |
Why?
|
| Medical Oncology | 1 | 2005 | 2349 | 0.030 |
Why?
|
| Foot | 1 | 1997 | 577 | 0.030 |
Why?
|
| Hepatic Encephalopathy | 2 | 2012 | 144 | 0.030 |
Why?
|
| Th1 Cells | 1 | 2018 | 1042 | 0.030 |
Why?
|
| Drug Resistance | 2 | 2001 | 1595 | 0.030 |
Why?
|
| Monitoring, Immunologic | 1 | 1993 | 100 | 0.030 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 1995 | 285 | 0.030 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2002 | 1890 | 0.030 |
Why?
|
| Prednisolone | 2 | 2004 | 327 | 0.030 |
Why?
|
| Perfusion | 2 | 2013 | 1402 | 0.030 |
Why?
|
| Immunoglobulin Isotypes | 2 | 1998 | 158 | 0.030 |
Why?
|
| Papio hamadryas | 1 | 2012 | 32 | 0.030 |
Why?
|
| Geography | 1 | 2015 | 654 | 0.030 |
Why?
|
| Self Care | 1 | 1998 | 797 | 0.030 |
Why?
|
| Microscopy, Fluorescence | 3 | 2009 | 2636 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 1999 | 3438 | 0.030 |
Why?
|
| Spleen | 1 | 1998 | 2296 | 0.030 |
Why?
|
| Cytokines | 3 | 2015 | 7445 | 0.030 |
Why?
|
| Postmenopause | 1 | 2001 | 2518 | 0.030 |
Why?
|
| Adenoma, Bile Duct | 1 | 1992 | 29 | 0.030 |
Why?
|
| Genotype | 2 | 2019 | 13042 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2012 | 10776 | 0.020 |
Why?
|
| Biomedical Research | 1 | 2008 | 3464 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 3 | 2002 | 2475 | 0.020 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2004 | 2763 | 0.020 |
Why?
|
| Cardiovascular Diseases | 3 | 2004 | 15649 | 0.020 |
Why?
|
| Child, Preschool | 6 | 2005 | 42650 | 0.020 |
Why?
|
| Hand | 1 | 1997 | 912 | 0.020 |
Why?
|
| Cell Line | 4 | 2009 | 15597 | 0.020 |
Why?
|
| Radiation Chimera | 1 | 2011 | 216 | 0.020 |
Why?
|
| DNA, Viral | 2 | 1999 | 2205 | 0.020 |
Why?
|
| Survival | 1 | 1992 | 160 | 0.020 |
Why?
|
| Antibodies, Viral | 2 | 1994 | 3211 | 0.020 |
Why?
|
| Interleukin-15 | 1 | 2012 | 185 | 0.020 |
Why?
|
| Pilot Projects | 2 | 2019 | 8731 | 0.020 |
Why?
|
| Kidney Tubules | 3 | 2001 | 448 | 0.020 |
Why?
|
| Erythrocyte Transfusion | 1 | 1996 | 575 | 0.020 |
Why?
|
| Cancer Vaccines | 1 | 1998 | 1042 | 0.020 |
Why?
|
| Immunohistochemistry | 4 | 2011 | 11120 | 0.020 |
Why?
|
| Exercise Therapy | 1 | 1998 | 941 | 0.020 |
Why?
|
| Learning Curve | 1 | 2012 | 232 | 0.020 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 1997 | 1517 | 0.020 |
Why?
|
| Internship and Residency | 1 | 2011 | 5949 | 0.020 |
Why?
|
| Hemostasis, Surgical | 1 | 2011 | 127 | 0.020 |
Why?
|
| Risk Factors | 7 | 2015 | 74962 | 0.020 |
Why?
|
| Ciprofloxacin | 1 | 1992 | 313 | 0.020 |
Why?
|
| Laparoscopy | 3 | 2009 | 2056 | 0.020 |
Why?
|
| Administration, Oral | 3 | 2000 | 4039 | 0.020 |
Why?
|
| Rupture, Spontaneous | 1 | 2011 | 365 | 0.020 |
Why?
|
| Medical Records | 1 | 1996 | 1412 | 0.020 |
Why?
|
| Massachusetts | 3 | 2015 | 8902 | 0.020 |
Why?
|
| Liver Diseases | 1 | 1999 | 1304 | 0.020 |
Why?
|
| Organ Specificity | 1 | 2015 | 1967 | 0.020 |
Why?
|
| Leg Dermatoses | 1 | 1989 | 20 | 0.020 |
Why?
|
| Biopsy, Needle | 3 | 2005 | 1627 | 0.020 |
Why?
|
| Leukapheresis | 1 | 2010 | 150 | 0.020 |
Why?
|
| Aging | 1 | 2008 | 8764 | 0.020 |
Why?
|
| Intracranial Pressure | 1 | 2012 | 325 | 0.020 |
Why?
|
| Intracranial Hypertension | 1 | 2012 | 193 | 0.020 |
Why?
|
| Metabolic Clearance Rate | 1 | 1989 | 363 | 0.020 |
Why?
|
| Cattle | 1 | 2015 | 3826 | 0.020 |
Why?
|
| ROC Curve | 1 | 2017 | 3623 | 0.020 |
Why?
|
| Mice, Inbred C3H | 1 | 2010 | 915 | 0.020 |
Why?
|
| Gene Knockout Techniques | 1 | 2012 | 808 | 0.020 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 1991 | 446 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2012 | 13697 | 0.020 |
Why?
|
| Mycobacterium Infections | 1 | 1989 | 122 | 0.020 |
Why?
|
| Fluconazole | 1 | 1989 | 156 | 0.020 |
Why?
|
| Cholesterol | 2 | 2004 | 2912 | 0.020 |
Why?
|
| Sex Distribution | 2 | 2005 | 2281 | 0.020 |
Why?
|
| bcl-X Protein | 1 | 2010 | 412 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2024 | 14481 | 0.020 |
Why?
|
| Health Services Needs and Demand | 1 | 1996 | 1407 | 0.020 |
Why?
|
| Blood Loss, Surgical | 1 | 2012 | 643 | 0.020 |
Why?
|
| Age Factors | 2 | 1996 | 18471 | 0.020 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 1 | 2010 | 263 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 2 | 1999 | 6085 | 0.020 |
Why?
|
| Macaca | 1 | 1990 | 417 | 0.020 |
Why?
|
| Blood Pressure | 3 | 2004 | 8541 | 0.020 |
Why?
|
| Hemodynamics | 1 | 1999 | 4199 | 0.020 |
Why?
|
| Endoscopy, Digestive System | 1 | 2011 | 357 | 0.020 |
Why?
|
| Anticoagulants | 1 | 2004 | 4843 | 0.020 |
Why?
|
| Aged, 80 and over | 6 | 2015 | 59686 | 0.020 |
Why?
|
| Interferons | 2 | 2004 | 716 | 0.020 |
Why?
|
| Fibrinogen | 2 | 2004 | 891 | 0.020 |
Why?
|
| Hypothermia, Induced | 1 | 2013 | 756 | 0.020 |
Why?
|
| Communicable Diseases | 1 | 1996 | 873 | 0.020 |
Why?
|
| DNA, Neoplasm | 1 | 1993 | 1748 | 0.020 |
Why?
|
| Aspartate Aminotransferases | 2 | 2003 | 414 | 0.020 |
Why?
|
| Postoperative Period | 2 | 2004 | 1830 | 0.020 |
Why?
|
| Injections, Intravenous | 2 | 2000 | 1379 | 0.020 |
Why?
|
| Protein Array Analysis | 1 | 2009 | 399 | 0.020 |
Why?
|
| Coculture Techniques | 1 | 2011 | 1342 | 0.020 |
Why?
|
| Hepatocyte Nuclear Factor 3-alpha | 1 | 2008 | 165 | 0.020 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 1999 | 1482 | 0.020 |
Why?
|
| Granuloma | 1 | 1989 | 329 | 0.020 |
Why?
|
| Postoperative Hemorrhage | 1 | 2011 | 419 | 0.020 |
Why?
|
| Personality Assessment | 1 | 2009 | 646 | 0.020 |
Why?
|
| Random Allocation | 3 | 1987 | 2397 | 0.020 |
Why?
|
| Inflammation | 2 | 2015 | 10863 | 0.020 |
Why?
|
| Safety | 2 | 2003 | 1159 | 0.020 |
Why?
|
| Intestinal Obstruction | 1 | 2011 | 435 | 0.020 |
Why?
|
| Papillomavirus Infections | 1 | 1999 | 1640 | 0.020 |
Why?
|
| Capillaries | 2 | 2001 | 756 | 0.020 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2002 | 3200 | 0.020 |
Why?
|
| Viral Load | 2 | 2008 | 3398 | 0.020 |
Why?
|
| BCG Vaccine | 1 | 1989 | 383 | 0.020 |
Why?
|
| Hyponatremia | 1 | 1989 | 280 | 0.020 |
Why?
|
| Nucleoside Deaminases | 1 | 1986 | 58 | 0.020 |
Why?
|
| Receptors, IgG | 1 | 1989 | 564 | 0.020 |
Why?
|
| Phenotype | 4 | 2017 | 16721 | 0.020 |
Why?
|
| Cause of Death | 2 | 2003 | 3728 | 0.020 |
Why?
|
| Immunophenotyping | 1 | 2011 | 1866 | 0.020 |
Why?
|
| Granzymes | 1 | 2008 | 278 | 0.020 |
Why?
|
| Sick Role | 1 | 1987 | 229 | 0.020 |
Why?
|
| Mycoses | 1 | 1989 | 386 | 0.020 |
Why?
|
| Diagnosis, Differential | 5 | 2008 | 13020 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 1990 | 2299 | 0.020 |
Why?
|
| Infant | 3 | 1999 | 36510 | 0.020 |
Why?
|
| Factor VIII | 1 | 1988 | 349 | 0.020 |
Why?
|
| Blood Group Incompatibility | 1 | 2006 | 134 | 0.020 |
Why?
|
| Diagnosis-Related Groups | 1 | 2007 | 448 | 0.020 |
Why?
|
| Blood Transfusion | 1 | 2012 | 1309 | 0.020 |
Why?
|
| Reference Values | 2 | 2005 | 4941 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 2 | 2010 | 6234 | 0.020 |
Why?
|
| Kidney Neoplasms | 1 | 2002 | 4303 | 0.020 |
Why?
|
| Monitoring, Intraoperative | 1 | 2012 | 950 | 0.020 |
Why?
|
| beta Catenin | 1 | 2010 | 1047 | 0.020 |
Why?
|
| Molecular Sequence Data | 2 | 1999 | 17626 | 0.020 |
Why?
|
| Psychophysiologic Disorders | 1 | 1987 | 223 | 0.020 |
Why?
|
| Viral Hepatitis Vaccines | 1 | 1985 | 72 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2011 | 2524 | 0.020 |
Why?
|
| Drug Interactions | 1 | 2009 | 1420 | 0.010 |
Why?
|
| Adoptive Transfer | 1 | 2007 | 824 | 0.010 |
Why?
|
| Multivariate Analysis | 2 | 2004 | 12092 | 0.010 |
Why?
|
| Costs and Cost Analysis | 1 | 1990 | 1669 | 0.010 |
Why?
|
| Lymphocyte Count | 1 | 2006 | 793 | 0.010 |
Why?
|
| Disease Progression | 2 | 2015 | 13646 | 0.010 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 3 | 1984 | 977 | 0.010 |
Why?
|
| Adenosine Deaminase | 1 | 1986 | 252 | 0.010 |
Why?
|
| Immune System | 1 | 2009 | 801 | 0.010 |
Why?
|
| Angiography | 1 | 2009 | 1598 | 0.010 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2011 | 1126 | 0.010 |
Why?
|
| Triglycerides | 1 | 1991 | 2465 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 1990 | 10377 | 0.010 |
Why?
|
| Glucocorticoids | 2 | 2003 | 2168 | 0.010 |
Why?
|
| Signal Transduction | 2 | 2011 | 23631 | 0.010 |
Why?
|
| Siblings | 1 | 2006 | 829 | 0.010 |
Why?
|
| Pulmonary Embolism | 1 | 1996 | 2587 | 0.010 |
Why?
|
| Sulfamethoxazole | 1 | 1982 | 51 | 0.010 |
Why?
|
| Interferon Type I | 2 | 1983 | 569 | 0.010 |
Why?
|
| Drainage | 1 | 2008 | 1184 | 0.010 |
Why?
|
| Base Sequence | 1 | 1993 | 12422 | 0.010 |
Why?
|
| Trimethoprim | 1 | 1982 | 79 | 0.010 |
Why?
|
| Pancreas | 1 | 1989 | 1702 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2013 | 8199 | 0.010 |
Why?
|
| Stroke Volume | 1 | 1996 | 5619 | 0.010 |
Why?
|
| Anaphylaxis | 1 | 2009 | 758 | 0.010 |
Why?
|
| Rosette Formation | 1 | 1981 | 152 | 0.010 |
Why?
|
| Complement C5b | 1 | 2001 | 9 | 0.010 |
Why?
|
| Pregnancy | 1 | 2003 | 30200 | 0.010 |
Why?
|
| Rats | 2 | 2013 | 23835 | 0.010 |
Why?
|
| Herpesviridae Infections | 1 | 1983 | 269 | 0.010 |
Why?
|
| Complement C5 | 1 | 2001 | 104 | 0.010 |
Why?
|
| Homocysteine | 1 | 2004 | 637 | 0.010 |
Why?
|
| Peritoneal Dialysis | 1 | 2002 | 160 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2017 | 10478 | 0.010 |
Why?
|
| Neutrophils | 2 | 2008 | 3785 | 0.010 |
Why?
|
| Decision Making | 1 | 2015 | 3953 | 0.010 |
Why?
|
| Extremities | 1 | 2006 | 870 | 0.010 |
Why?
|
| Blood Glucose | 2 | 2001 | 6430 | 0.010 |
Why?
|
| Cell Survival | 1 | 2010 | 5792 | 0.010 |
Why?
|
| Family Planning Services | 1 | 2003 | 279 | 0.010 |
Why?
|
| Monocytes | 1 | 1989 | 2595 | 0.010 |
Why?
|
| Probability | 1 | 2005 | 2482 | 0.010 |
Why?
|
| Colonoscopy | 1 | 2008 | 1412 | 0.010 |
Why?
|
| Technetium Tc 99m Sulfur Colloid | 1 | 1999 | 63 | 0.010 |
Why?
|
| Cell Movement | 1 | 1992 | 5215 | 0.010 |
Why?
|
| Herpes Simplex | 2 | 1983 | 470 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2005 | 2862 | 0.010 |
Why?
|
| Hepatitis | 1 | 1981 | 228 | 0.010 |
Why?
|
| Patient Readmission | 1 | 1994 | 3312 | 0.010 |
Why?
|
| Age Distribution | 1 | 2005 | 2877 | 0.010 |
Why?
|
| Cytological Techniques | 1 | 1981 | 218 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 1987 | 4859 | 0.010 |
Why?
|
| Complement C3 Convertase, Alternative Pathway | 1 | 1999 | 7 | 0.010 |
Why?
|
| C-Peptide | 1 | 2001 | 443 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2010 | 8326 | 0.010 |
Why?
|
| Ureteral Diseases | 1 | 1999 | 63 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2015 | 14784 | 0.010 |
Why?
|
| Antigens, Viral, Tumor | 1 | 1999 | 153 | 0.010 |
Why?
|
| Brain Injuries | 1 | 2010 | 2059 | 0.010 |
Why?
|
| Nucleic Acid Synthesis Inhibitors | 1 | 1998 | 109 | 0.010 |
Why?
|
| Models, Biological | 1 | 1995 | 9493 | 0.010 |
Why?
|
| Hemolytic-Uremic Syndrome | 1 | 1999 | 106 | 0.010 |
Why?
|
| Alcoholism | 1 | 2009 | 1982 | 0.010 |
Why?
|
| Immunosorbent Techniques | 1 | 1998 | 174 | 0.010 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2006 | 1813 | 0.010 |
Why?
|
| Uric Acid | 1 | 2004 | 806 | 0.010 |
Why?
|
| Disease-Free Survival | 2 | 2000 | 6856 | 0.010 |
Why?
|
| Autoimmune Diseases | 1 | 2010 | 2257 | 0.010 |
Why?
|
| Macaca mulatta | 2 | 1995 | 2362 | 0.010 |
Why?
|
| Endothelium, Vascular | 1 | 1990 | 4427 | 0.010 |
Why?
|
| Antibodies, Neoplasm | 1 | 1999 | 283 | 0.010 |
Why?
|
| Nephritis, Interstitial | 1 | 1999 | 158 | 0.010 |
Why?
|
| Enteritis | 1 | 1999 | 164 | 0.010 |
Why?
|
| Hemoperfusion | 1 | 1997 | 13 | 0.010 |
Why?
|
| Hypersensitivity, Delayed | 1 | 1998 | 491 | 0.010 |
Why?
|
| Agglutination Tests | 1 | 1997 | 43 | 0.010 |
Why?
|
| Fibrinolysis | 1 | 1998 | 331 | 0.010 |
Why?
|
| Blood | 1 | 2000 | 597 | 0.010 |
Why?
|
| Delirium | 1 | 2009 | 1695 | 0.010 |
Why?
|
| Fluorescent Antibody Technique, Direct | 1 | 1997 | 65 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2004 | 4588 | 0.010 |
Why?
|
| Blood Component Removal | 1 | 1998 | 132 | 0.010 |
Why?
|
| Antidepressive Agents | 1 | 2009 | 2913 | 0.010 |
Why?
|
| Antigens, Heterophile | 1 | 1997 | 70 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 1998 | 1553 | 0.010 |
Why?
|
| Cysts | 1 | 2002 | 685 | 0.010 |
Why?
|
| Remission Induction | 1 | 2002 | 2407 | 0.010 |
Why?
|
| Models, Chemical | 1 | 1999 | 611 | 0.010 |
Why?
|
| Clinical Competence | 1 | 2012 | 4848 | 0.010 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 1998 | 425 | 0.010 |
Why?
|
| Lung | 1 | 2015 | 10089 | 0.010 |
Why?
|
| Cohort Studies | 3 | 2006 | 41795 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2012 | 15455 | 0.010 |
Why?
|
| Antipsychotic Agents | 1 | 2009 | 3080 | 0.010 |
Why?
|
| Blood Urea Nitrogen | 1 | 1995 | 187 | 0.010 |
Why?
|
| Case-Control Studies | 2 | 2005 | 22296 | 0.010 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2000 | 669 | 0.010 |
Why?
|
| Radionuclide Imaging | 1 | 1999 | 1998 | 0.010 |
Why?
|
| Immunoglobulin A | 1 | 1978 | 991 | 0.010 |
Why?
|
| Prevalence | 2 | 2002 | 15872 | 0.010 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 1995 | 287 | 0.010 |
Why?
|
| Species Specificity | 1 | 1999 | 2417 | 0.010 |
Why?
|
| Antigens, Viral | 1 | 1998 | 992 | 0.010 |
Why?
|
| Diabetes Complications | 1 | 2001 | 1322 | 0.010 |
Why?
|
| Cholesterol, LDL | 1 | 2004 | 2398 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 2007 | 5538 | 0.010 |
Why?
|
| Endocardium | 1 | 1995 | 249 | 0.010 |
Why?
|
| Health Planning | 1 | 1996 | 232 | 0.010 |
Why?
|
| Myocardium | 2 | 1999 | 4788 | 0.010 |
Why?
|
| Bacterial Infections | 2 | 1981 | 1397 | 0.010 |
Why?
|
| Microcirculation | 1 | 1999 | 1282 | 0.010 |
Why?
|
| Psychotic Disorders | 1 | 2009 | 3279 | 0.010 |
Why?
|
| Advisory Committees | 1 | 1998 | 797 | 0.010 |
Why?
|
| Eosinophils | 1 | 1998 | 953 | 0.010 |
Why?
|
| Immunocompromised Host | 1 | 1999 | 863 | 0.010 |
Why?
|
| Government Regulation | 1 | 1998 | 525 | 0.010 |
Why?
|
| Cross-Sectional Studies | 2 | 2005 | 26375 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2008 | 12558 | 0.010 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 1994 | 412 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 1986 | 4936 | 0.010 |
Why?
|
| Genetic Engineering | 1 | 1998 | 936 | 0.010 |
Why?
|
| Pentamidine | 1 | 1992 | 44 | 0.010 |
Why?
|
| New England | 1 | 1996 | 1058 | 0.010 |
Why?
|
| Blood Coagulation | 1 | 1999 | 1161 | 0.010 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 1998 | 1105 | 0.010 |
Why?
|
| Substance-Related Disorders | 1 | 2009 | 4429 | 0.010 |
Why?
|
| C-Reactive Protein | 1 | 2004 | 3857 | 0.010 |
Why?
|
| CD4 Lymphocyte Count | 1 | 1998 | 2596 | 0.010 |
Why?
|
| Cross Infection | 1 | 1981 | 1426 | 0.010 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2000 | 2202 | 0.010 |
Why?
|
| Lymphoid Tissue | 1 | 1993 | 446 | 0.010 |
Why?
|
| Double-Blind Method | 4 | 1992 | 12456 | 0.010 |
Why?
|
| Cross Reactions | 1 | 1993 | 828 | 0.010 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 1992 | 242 | 0.010 |
Why?
|
| Risk | 3 | 1992 | 9636 | 0.010 |
Why?
|
| Hypertension | 1 | 1990 | 8615 | 0.010 |
Why?
|
| Contrast Media | 1 | 1983 | 5336 | 0.010 |
Why?
|
| Aerosols | 1 | 1992 | 637 | 0.010 |
Why?
|
| United States Food and Drug Administration | 1 | 1998 | 1672 | 0.010 |
Why?
|
| Radiopharmaceuticals | 1 | 1999 | 2734 | 0.010 |
Why?
|
| Emergencies | 1 | 1996 | 1219 | 0.010 |
Why?
|
| Cryptococcus neoformans | 1 | 1989 | 121 | 0.000 |
Why?
|
| Intraoperative Complications | 1 | 1995 | 1176 | 0.000 |
Why?
|
| Candida | 1 | 1989 | 172 | 0.000 |
Why?
|
| Cell Division | 1 | 1995 | 4479 | 0.000 |
Why?
|
| Leukocytes | 1 | 1995 | 2030 | 0.000 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2011 | 20765 | 0.000 |
Why?
|
| Dendritic Cells | 1 | 1998 | 2749 | 0.000 |
Why?
|
| Heart Rate | 1 | 1999 | 4218 | 0.000 |
Why?
|
| Adjustment Disorders | 1 | 1987 | 68 | 0.000 |
Why?
|
| Pain | 1 | 2002 | 5103 | 0.000 |
Why?
|
| Insulin | 1 | 2001 | 6607 | 0.000 |
Why?
|
| Gene Expression | 1 | 1999 | 7598 | 0.000 |
Why?
|
| Dipeptidyl Peptidase 4 | 1 | 1986 | 93 | 0.000 |
Why?
|
| Immunity, Innate | 1 | 1998 | 3078 | 0.000 |
Why?
|
| HLA-DR Antigens | 1 | 1987 | 607 | 0.000 |
Why?
|
| Patient Care Team | 1 | 1995 | 2529 | 0.000 |
Why?
|
| Kidney Tubules, Proximal | 1 | 1986 | 385 | 0.000 |
Why?
|
| Hepatitis B Vaccines | 1 | 1985 | 178 | 0.000 |
Why?
|
| Macrophages | 1 | 1998 | 5796 | 0.000 |
Why?
|
| Clone Cells | 1 | 1987 | 1671 | 0.000 |
Why?
|
| Arteries | 1 | 1987 | 1126 | 0.000 |
Why?
|
| Urography | 1 | 1983 | 316 | 0.000 |
Why?
|
| Arteriovenous Shunt, Surgical | 1 | 1984 | 291 | 0.000 |
Why?
|
| Infectious Mononucleosis | 1 | 1981 | 133 | 0.000 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2004 | 12241 | 0.000 |
Why?
|
| Genetics, Population | 1 | 1984 | 942 | 0.000 |
Why?
|
| Pneumonia | 2 | 1981 | 2163 | 0.000 |
Why?
|
| Evaluation Studies as Topic | 1 | 1981 | 1629 | 0.000 |
Why?
|
| Cystitis | 1 | 1979 | 96 | 0.000 |
Why?
|
| Glycoproteins | 1 | 1986 | 2204 | 0.000 |
Why?
|
| Mice, Inbred Strains | 1 | 1981 | 1769 | 0.000 |
Why?
|
| Psychotherapy | 1 | 1987 | 1656 | 0.000 |
Why?
|
| Urine | 1 | 1979 | 363 | 0.000 |
Why?
|
| Herpesvirus 4, Human | 1 | 1983 | 1082 | 0.000 |
Why?
|
| Central Nervous System Diseases | 1 | 1981 | 523 | 0.000 |
Why?
|
| Sepsis | 2 | 1981 | 2601 | 0.000 |
Why?
|
| Simplexvirus | 1 | 1979 | 805 | 0.000 |
Why?
|
| Virus Diseases | 1 | 1981 | 723 | 0.000 |
Why?
|
| Polymorphism, Genetic | 1 | 1984 | 4250 | 0.000 |
Why?
|
| Immunotherapy | 1 | 1986 | 4738 | 0.000 |
Why?
|
| Fever | 1 | 1977 | 1620 | 0.000 |
Why?
|
| Cell Differentiation | 1 | 1986 | 11668 | 0.000 |
Why?
|
| Anti-Bacterial Agents | 1 | 1981 | 7463 | 0.000 |
Why?
|
| Pneumonia, Viral | 1 | 1977 | 3241 | 0.000 |
Why?
|